The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024 ReportsWeb.com adds “The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024� to its Store The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access - and this is only the OTC market - what has the growth been throughout the whole Chinese pharma sector? This report will tell you. Report Url @ http://www.reportsweb.com/the-chinese-pharmaceutical-market-to-2024-commercial-andstrategic-developments-in-the-chinese-pharmaceutical-market-to-2024 China's pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market? Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world's diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types - your company must capture a segment of this market TODAY. Anti-Counterfeiting and anti-corruption - How the Chinese market is changing Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report. Request for Sample: http://www.reportsweb.com/inquiry&RW0001274188/sample Increased inward investment from multiple 'Big Pharma' companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel. Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market. Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011 Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015 In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure. Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008
Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001274188/discount This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment. Discover exactly what the industry leaders are doing TODAY Industry information sourced exclusively for this report. This information is not available anywhere else Utilising primary and secondary research sources, Publisher have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field - This information is not available anywhere else. About Us: ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. Contact Us: Phone: +1-646-491-9876 Email Id: sales@reportsweb.com